SLC2A6

Across TCGA pan-cancer cohorts, SLC2A6 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC2A6 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SLC2A6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC2A6 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC and PDAC are the cancer types where SLC2A6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	1.000	0.360	.002	10	view →
PDAC	OS	Tertile	III,IV	0.508	0.932	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SLC2A6–LSCC (DFS)

Open the LSCC breakdown →